157033-23-3

Basic information

• Product Name: (2,5-DIFLUORO-PHENYL)-ACETYL CHLORIDE
• Synonyms: (2,5-DIFLUORO-PHENYL)-ACETYL CHLORIDE
• CAS NO: 157033-23-3
• Molecular Formula: C₈H₅ClF₂O
• Molecular Weight: 190.57
• Mol File: 157033-23-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 217.1±30.0 °C(Predicted)
• Appearance: /
• Density: 1.369±0.06 g/cm3(Predicted)
• CAS DataBase Reference: (2,5-DIFLUORO-PHENYL)-ACETYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (2,5-DIFLUORO-PHENYL)-ACETYL CHLORIDE(157033-23-3)
• EPA Substance Registry System: (2,5-DIFLUORO-PHENYL)-ACETYL CHLORIDE(157033-23-3)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 157033-23-3(Hazardous Substances Data)

Usage

Description

(2,5-DIFLUORO-PHENYL)-ACETYL CHLORIDE is a chemical compound that is primarily used in organic synthesis and pharmaceutical development. It is an acetyl chloride derivative with a 2,5-difluoro-phenyl group attached to the acetyl group. (2,5-DIFLUORO-PHENYL)-ACETYL CHLORIDE is highly reactive and is often used as an intermediate in the production of various compounds, such as pharmaceuticals and agrochemicals. It is also utilized in research and development settings for the synthesis of new organic compounds and chemical reactions.

Uses

Used in Pharmaceutical Industry:
(2,5-DIFLUORO-PHENYL)-ACETYL CHLORIDE is used as an intermediate in the synthesis of various pharmaceutical compounds for its reactivity and ability to form new organic compounds.
Used in Agrochemical Industry:
(2,5-DIFLUORO-PHENYL)-ACETYL CHLORIDE is used as a precursor in the production of agrochemicals, contributing to the development of new compounds for agricultural applications.
Used in Research and Development:
(2,5-DIFLUORO-PHENYL)-ACETYL CHLORIDE is used as a reactive intermediate in research and development settings for the synthesis of novel organic compounds and the study of chemical reactions.
Safety Precautions:
Due to its reactivity and potential hazards, (2,5-DIFLUORO-PHENYL)-ACETYL CHLORIDE should be handled with care, and proper safety precautions should be taken when working with this compound.

Upstream product

• 85068-27-5 2,5-difluorophenylacetic acid 

Downstream Products

• 764667-66-5 5-[1-hydroxy-2-(2,5-difluorophenyl)ethylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 767352-24-9 methyl 4-(2,5-difluorophenyl)-3-oxobutanoate 
• 848667-50-5 methyl (3S)-4-(2,5-difluorophenyl)-3-hydroxybutanoate 
• 848667-53-8 (R)-3-Amino-4-(2,5-difluoro-phenyl)-butyric acid methyl ester 
• 848667-51-6 (3S)-4-(2,5-difluorophenyl)-3-hydroxybutanoic acid 
• 767352-26-1 N-benzyloxy-4(R)-[1-methyl-(2,5-difluorobenzyl)]-2-oxoazetidine 
• 767352-25-0 N-benzyloxy-4-(2,5-difluorophenyl)-3(S)-hydroxybutanamide 
• 486459-98-7 (3R)-3-[(1,1-dimethylethoxycarbonyl)amino]-4-(2,5-difluorophenyl)butanoic acid 
• 1258517-58-6 (Z)-ethyl 2-amino-2-(2-(2,5-difluorophenyl)acetoxyimino)acetate 

Relevant articles and documents

Phosphonic acid analogs of fluorophenylalanines as inhibitors of human and porcine aminopeptidases N: Validation of the importance of the substitution of the aromatic ring

A library of phosphonic acid analogs of phenylalanine substituted with fluorine, chlorine and trifluoromethyl moieties on the aromatic ring was synthesized and evaluated for inhibitory activity against human (hAPN) and porcine (pAPN) aminopeptidases. Fluorogenic screening indicated that these analogs are micromolar or submicromolar inhibitors, both enzymes being more active against hAPN. In order to better understand the mode of the action of the most active compounds, molecular modeling was used. It confirmed that aminophosphonic portion of the enzyme is bound nearly identically in the case of all the studied compounds, whereas the difference in activity results from the placement of aromatic side chain of an inhibitor. Interestingly, both enantiomers of the individual compounds are usually bound quite similarly.

INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.